2025 Financial Guidance Sight Sciences raises its revenue guidance expectations for full year 2025 to $76.0 million to $78.0 million, representing a 2% to 5% decline compared to full year 2024 revenue ...
The Healthy @Reader's Digest on MSN
“What I Wish I’d Known About Cataract Surgery”: A Doctor Details What Patients Should Know About a Common Procedure
What are the signs that show I need cataract surgery? "There are several key signs that someone may need cataract surgery," ...
Avisi Technologies has released positive 12-month clinical data on the VisiPlate Aqueous Shunt from the VITA Trial. The VITA ...
Scientists at Mizzou have identified two small molecules, agmatine and thiamine, that could both reveal and fight glaucoma.
Sight Sciences’ management is scheduled to present at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 8:20 am PT / 11:20 am ET. Sight Sciences’ management is scheduled to ...
With most of its sales now coming from the US, glaucoma device maker Nova Eye Medical is steering a course through global trade turbulence.
Please provide your email address to receive an email when new articles are posted on . The first eye surgery outcome was the only factor that affected the second eye surgery outcome. Cumulative ...
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing ...
Sight Sciences (Nasdaq:SGHT) today announced new clinical data supporting its Omni minimally invasive glaucoma surgery (MIGS) device. Menlo Park, California–based Sight Sciences conducted a systematic ...
Sight Sciences Inc. (NASDAQ:SGHT) on Tuesday announced that UnitedHealthcare has updated its Glaucoma Surgical Treatments policy to cover goniotomy, trabeculotomy, canaloplasty (ab interno), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback